Actively Recruiting
DNA Methylation and Vascular Function
Led by University of Illinois at Chicago · Updated on 2025-09-15
80
Participants Needed
1
Research Sites
359 weeks
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main objective is to examine DNA hypomethylation as an underlying mechanism for the increased production of inflammatory cytokines and the impaired vascular function in obese individuals and as a potential target for nonpharmacological preventive/therapeutic interventions such as aerobic exercise.
CONDITIONS
Official Title
DNA Methylation and Vascular Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI 6 35 kg/m2
- Between ages 18-50 years
- Not pregnant
- Approved for a bariatric surgery
You will not qualify if you...
- Current cancer, heart, kidney, liver, or gallbladder disease
- Acute or chronic inflammatory diseases including rheumatoid arthritis, lupus, autoimmune and genetic diseases
- Pregnant women
- Current smokers
- Current abuse of alcohol or drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
A
Abeer Mohamed, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here